Heron Therapeutics (NASDAQ:HRTX) said first-quarter 2026 results were pressured by seasonal factors and severe winter weather, but management reaffirmed its full-year outlook and pointed to improving momentum exiting the quarter.
Chief Executive Officer Craig Collard said the company entered 2026 with “tremendous momentum” following a strong fourth quarter, but January was affected by co-pay resets, insurance adjustments and two weeks of severe weather that disrupted elective surgeries. Collard described January as “our most difficult month since I joined the company,” while emphasizing that March net sales exceeded $15 million.
